Skip to content
1st Counsel – Lifestyle
Author:
Novo Nordisk A/S
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
September 29, 2026
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
July 21, 2026